Work

Comparison of camrelizumab, pembrolizumab, tislelizumab, and sintilimab as first-line treatment in patients with non-small cell lung cancer: a retrospective study

Year: 2025

Type: article

Abstract: Background: Immune checkpoint inhibitors (ICIs) have significantly altered the first-line treatment paradigm for non-small cell lung cancer (NSCLC) without driver gene alterations. The efficacy and safety of different programmed cell death protein-1 (PD-1) inhibitors in the treatment of advanced NSCLC in Chinese real-world clinical practice remain unclear. This study aimed to analyze the efficacy and safety of camrelizumab, pembrolizumab, tislelizumab, and sintilimab retrospectively as first-line treatment options for advanced NSCLC in Chinese real-world applications. Methods: A total of 452 NSCLC patients treated with camrelizumab, pembrolizumab, tislelizumab, or sintilimab as first-line treatment between January 2019 and June 2023 in Jiangsu Cancer Hospital were retrospectively evaluated. Adverse events and patient responses were assessed using Common Terminology Criteria for Adverse Events v5.0 and Response Evaluation Criteria for Solid Tumors v1.1. The progression-free survival (PFS) was estimated using the Kaplan-Meier method or Cox survival regression model and compared using the log-rank test. Results: 9.79 months, P=0.31). Similar incidences of immune-related adverse events (irAEs) at any grade were observed in different PD-1 inhibitors (P=0.21). Similarly, no statistically significant differences in the incidence of grade 3 and 4 irAEs were observed (P=0.63). The Cox proportional hazard modeling analysis suggested that physical performance, occurrence of irAEs were all connected with the prognosis. The type of PD-1 inhibitors was not an independent prognostic factor affecting PFS. Conclusions: Camrelizumab, pembrolizumab, tislelizumab, and sintilimab possess similar efficacy as first-line treatment options for patients with advanced NSCLC in Chinese clinical practice. Any grade or grade ≥3 irAEs are comparable between the four PD-1 inhibitors.

Source: Journal of Thoracic Disease

DOI: 10.21037/jtd-24-1495

Authors: Xiaoqi Yan, Yizong Wang, Fei Wu, Guoren Zhou, Jiannan Shen, Shaorong Yu

Institutions: Jiangsu Cancer Hospital, Nanjing Medical University

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

Funders: National Natural Science Foundation of China, Government of Jiangsu Province